Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Cash & Current Investments (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Cash & Current Investments for 15 consecutive years, with $10.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments fell 14.84% year-over-year to $10.9 million, compared with a TTM value of $10.9 million through Oct 2025, down 14.84%, and an annual FY2025 reading of $10.9 million, down 14.84% over the prior year.
  • Cash & Current Investments was $10.9 million for Q4 2025 at Pharma-Bio Serv, up from $10.7 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $19.0 million in Q1 2021 and bottomed at $10.4 million in Q2 2025.
  • Average Cash & Current Investments over 5 years is $14.2 million, with a median of $14.4 million recorded in 2022.
  • The sharpest move saw Cash & Current Investments grew 24.47% in 2021, then fell 22.75% in 2025.
  • Year by year, Cash & Current Investments stood at $17.5 million in 2021, then fell by 17.21% to $14.5 million in 2022, then increased by 3.56% to $15.0 million in 2023, then fell by 14.9% to $12.7 million in 2024, then dropped by 14.84% to $10.9 million in 2025.
  • Business Quant data shows Cash & Current Investments for PBSV at $10.9 million in Q4 2025, $10.7 million in Q3 2025, and $10.4 million in Q2 2025.